Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs SYSCO Corporation — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while SYSCO Corporation trades at $78.14 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 3.1× Halozyme Therapeutics Inc. Common Stock's market cap, and SYSCO Corporation pays a 2.81% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and SYSCO Corporation for 77 Days on average.
| HALO | SYY | |
|---|---|---|
Market Cap | $12.58B | $38.47B |
Volume | 2,179,278 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $115.22 | $91.16 |
52-Week Low | $61.63 | $69.30 |
Typical Hold Time | 1 Days | 77 Days |
Enterprise Value | $14.49B | $51.65B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sysco (SYY) trades at $78.20, up 1.84% with neutral technical signals and strong institutional support. The stock shows solid fundamentals with $81.37B revenue, 2.08% net margin, and attractive valuation at P/E 21.37 and P/S 0.44. Recent corporate actions include a $0.55 dividend and $1B stock offering, while the company reaffirmed fiscal 2027 guidance and launched a $500M AI efficiency program.
Sysco presents a balanced investment case with 60% analyst buy ratings and $85.75 consensus target offering 9.6% upside. The food distribution leader benefits from consistent revenue growth and AI-driven efficiency initiatives, though margin pressure and competitive threats warrant monitoring. Current valuation appears reasonable given the company's market position and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
